| Market Capitalization (Millions $) |
272 |
| Shares
Outstanding (Millions) |
190 |
| Employees |
288 |
| Revenues (TTM) (Millions $) |
180 |
| Net Income (TTM) (Millions $) |
-21 |
| Cash Flow (TTM) (Millions $) |
8 |
| Capital Exp. (TTM) (Millions $) |
3 |
Cerus Corporation
Cerus Corporation is a biopharmaceutical company that has been dedicated to providing solutions for the enhancement of blood safety throughout the world since 1991. Their headquarters are located in Concord, California, and the company has additional facilities in France, Germany, and Switzerland.
Cerus Corporation focuses on the development of innovative technologies that can help prevent the transmission of diseases through blood transfusions. Their primary product is the INTERCEPT Blood System, which provides a broad-spectrum solution for the reduction of pathogens present in donated blood. It is a unique and proprietary technology that works by incorporating an FDA-approved chemical compound, known as amotosalen, to inactivate viruses, bacteria, and parasites in blood products.
The INTERCEPT Blood System targets the transfusion needs of individual patients by customizing blood components to meet their specific needs. This technology can also reduce the risk of transfusion-transmitted infections, such as dengue, Zika, chikungunya, and malaria. As such, it is becoming increasingly adopted in countries around the world, especially those with a high risk of disease transmission through transfusions.
Cerus Corporation's products and technologies have been approved by several regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company collaborates with several Worldwide Health Organisations, blood centers, and hospitals around the world. The INTERCEPT Blood System is used by over 150 centers in 30 countries, with over 5 million INTERCEPT-treated platelet and plasma units in circulation.
The company's management team comprises experts with vast experience in the health sector, which includes the commercialization of innovative blood products, and the successful registration of new pharmaceutical and medical device products globally.
Cerus Corporation is committed to continuously providing innovative products and services to meet necessary patient needs. With a commitment to excellence in research, development, and regulatory clinical trial programs, Cerus Corporation is at the forefront of reducing the risk of blood-borne diseases and ensuring patient safety in transfusion therapies.
Company Address: 1220 Concord Avenue Concord 94520 CA
Company Phone Number: 288-6000 Stock Exchange / Ticker: NASDAQ CERS
|
1.76% 
69.72 %